![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Lunit AI Analysis Software for Cancer Protein PD-L1 Gets CE-IVD Mark
Lunit AI Analysis Software for Cancer Protein PD-L1 Gets CE-IVD Mark
South Korea-based Lunit has received a CE-IVD mark for its artificial intelligence (AI) analysis software that focuses on the cancer-associated protein PD-L1.
The Scope PD-L1 TPS software, which delivers a tumor proportion score (TPS), was “trained” to identify the biomarker using more than 1 million cancer cell images. The software precisely analyzes PD-L1 biomarker expression and then classifies the PD-L1 TPS into three groups: 50 percent or more, 1-49 percent and 0 percent. The score helps pathologists in assessing the status of their cancer patients.
Lunit said it plans to launch the Lunit Scope PD-L1 software in Europe in the second half of this year.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct